Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press31710.17650/1726-9776-2012-8-3-43-50DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыряTHE DIAGNOSIS AND PREDICTION OF NON-MUSCLE INVASIVE BLADDER CANCER RECURRENCE, BY APPLYING CLINICAL METHODS AND FISH ANALYSIS (A REVIEW OF LITERATURE)ДИАГНОСТИКА И ПРОГНОЗИРОВАНИЕ РЕЦИДИВА НЕМЫШЕЧНО-ИНВАЗИВНОГО РАКА МОЧЕВОГО ПУЗЫРЯ ПРИ ПОМОЩИ КЛИНИЧЕСКИХ МЕТОДОВ И FISH-АНАЛИЗА (ОБЗОР ЛИТЕРАТУРЫ)TroyanovA. V.ТрояновА. В.
Russian Federation
alex_troy@mail.ruMedical Radiology Research Center, Ministry of Health of the Russian Federation, ObninskМРНЦ МЗ РФ, Обнинск300920128343500608201406082014https://oncourology.abvpress.ru/oncur/article/view/317

The review deals with the-state-of-the-art of diagnosis and prediction of non-muscle invasive bladder cancer (BC). It gives data on the chromosomal abnormalities identified in urothelial cancer cells according to the results of trials. The development of a procedure for FISH diagnosis of BC is noted to be warranted. An algorithm for interpreting the result of the FISH analysis is given. The use of data on chromosomal abnormalities as additional predictors of the course of non-muscle invasive BC is described. The application of the FISH technique in assessing the results of adjuvant treatment in patients with non-muscle invasive BC is also depicted. In summary, the main problems in the existing algorithms for its diagnosis and prediction, by employing the FISH technique, are indicated.

Обзорная статья посвящена современному состоянию проблемы диагностики и прогнозирования немышечно-инвазивного (НМИ) рака мочевого пузыря (РМП). Приведены данные о выявленных хромосомных нарушениях в клетках уротелиального рака по результатам исследований. Отмечена обоснованность разработки методики FISH-диагностики РМП, приведен алгоритм интерпретации результата FISH-анализа.Описано использование данных о хромосомных нарушениях в качестве дополнительных факторов прогноза течения НМИ РМП.Также описано использование FISH-метода в оценке результатов адъювантного лечения больных НМИ РМП. В заключении указаны основные проблемы в существующих алгоритмах диагностики и прогнозирования с использованием FISH-метода.

non-muscle invasive bladder cancer, chromosomal abnormalitiesfluorescence in situ hybridizationrecurrenceнемышечно-инвазивный рак мочевого пузыряхромосомные нарушенияфлуоресцентная in situ гибридизациярецидив1. Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Под ред. М.И. Давыдова, Е.М. Аксель. Вестник РОНЦ им. Н.Н. Блохина РАМН. М., 2011; 22, № 3 (85), прил. 1.Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Под ред. М.И. Давыдова, Е.М. Аксель. Вестник РОНЦ им. Н.Н. Блохина РАМН. М., 2011; 22, № 3 (85), прил. 1.2. Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2012.Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2012.3. Sobin L.H., Gospodarowicz M.K., Wittekind Ch. Eds. TNM Classification of Malignant Tumors, 7th ed. Wiley-Blackwell, Oxford 2009. 310 p.Sobin L.H., Gospodarowicz M.K., Wittekind Ch. Eds. TNM Classification of Malignant Tumors, 7th ed. Wiley-Blackwell, Oxford 2009. 310 p.4. Babjuk M., Oosterlinck W., Sylvester R. et al. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update. Eur Urol 2011;59:997−1008.Babjuk M., Oosterlinck W., Sylvester R. et al. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update. Eur Urol 2011;59:997−1008.5. Клиническая онкоурология. Под ред. Б.П. Матвеева. М., 2011; с. 283.Клиническая онкоурология. Под ред. Б.П. Матвеева. М., 2011; с. 283.6. Sylvester R.J., van der Meijden A.P., Oosterlinck W. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466−77.Sylvester R.J., van der Meijden A.P., Oosterlinck W. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466−77.7. Reeder J., O'Connell M.J., Yang Z. et al. DNA cytometry and chromosome 9 abberations by fluorescence in situ hybridization of irrigation speciment from bladder cancer patients. Urology 1998;51(Suppl 5A):58−61.Reeder J., O'Connell M.J., Yang Z. et al. DNA cytometry and chromosome 9 abberations by fluorescence in situ hybridization of irrigation speciment from bladder cancer patients. Urology 1998;51(Suppl 5A):58−61.8. Inoue T., Nasu Y., Tsushima T. et al. Chromosomal numerical aberrations of exfoliated cells in the urine detected by fluorescence in situ hybridization: clinical implication for the detection of bladder cancer. Urol Res 2000;28:57−61.Inoue T., Nasu Y., Tsushima T. et al. Chromosomal numerical aberrations of exfoliated cells in the urine detected by fluorescence in situ hybridization: clinical implication for the detection of bladder cancer. Urol Res 2000;28:57−61.9. Ishiwata S., Takahashi S., Hommaet Y. et al. Noninvasive detection and prediction of bladder cancer by fluorescence in situ hybridization analysis of exfoliated urothelial cells in voided urine. Urology 2001;57:811−5.Ishiwata S., Takahashi S., Hommaet Y. et al. Noninvasive detection and prediction of bladder cancer by fluorescence in situ hybridization analysis of exfoliated urothelial cells in voided urine. Urology 2001;57:811−5.10. Pycha A., Mian C., Haitel A. et al. Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive ( stage Ta) bladder cancer. J Urol 1997; 157:2116−9.Pycha A., Mian C., Haitel A. et al. Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive ( stage Ta) bladder cancer. J Urol 1997; 157:2116−9.11. Marano A., Pan Y., Li C. et al. Chromosomal numerical aberration detected by fluorescence in situ hybridization on bladder washing from patients with bladder cancer. Eur Urol 2000;37:358−65.Marano A., Pan Y., Li C. et al. Chromosomal numerical aberration detected by fluorescence in situ hybridization on bladder washing from patients with bladder cancer. Eur Urol 2000;37:358−65.12. Zhang F.F., Arber D.A., Wilson T.G. et al. Toward the validation of aneusomy detection by fluorescence in situ hybridization bladder cancer: comparative analysis with cytology, cytogenetics and clinical features predicts recurrence and defines clinical testing limitations. Clin Cancer Res 1997; 3(12 Pt1):2317−28.Zhang F.F., Arber D.A., Wilson T.G. et al. Toward the validation of aneusomy detection by fluorescence in situ hybridization bladder cancer: comparative analysis with cytology, cytogenetics and clinical features predicts recurrence and defines clinical testing limitations. Clin Cancer Res 1997; 3(12 Pt1):2317−28.13. Awata S., Sakagami H., Tozawa K. et al. Aberration chromosome 8 and 11 in bladder cancer detected by fluorescence in situ hybridization. Urol Res 2000;28:185−90.Awata S., Sakagami H., Tozawa K. et al. Aberration chromosome 8 and 11 in bladder cancer detected by fluorescence in situ hybridization. Urol Res 2000;28:185−90.14. Cajulis R., George K. Haines III, Denise Frias-Hidvegi et al. Cytology, flow cytometry image analysis and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washing. Diagn Cytophatol 1995; 13:214−24.Cajulis R., George K. Haines III, Denise Frias-Hidvegi et al. Cytology, flow cytometry image analysis and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washing. Diagn Cytophatol 1995; 13:214−24.15. Jiang F., Caraway N.P., Sabichi A.L. et al. Centrosomal abnormality is common in and a potential biomarker for bladder cancer. Int J Cancer 2003;106(5):661−5.Jiang F., Caraway N.P., Sabichi A.L. et al. Centrosomal abnormality is common in and a potential biomarker for bladder cancer. Int J Cancer 2003;106(5):661−5.16. Wang M.R., Perissel B., Taillandier J. et al. Nonrandom changes of chromosome 10 in bladder cancer. Detection by FISH to interphase nuclei. Cancer Genet Cytogenet 1994;73(1);8−10.Wang M.R., Perissel B., Taillandier J. et al. Nonrandom changes of chromosome 10 in bladder cancer. Detection by FISH to interphase nuclei. Cancer Genet Cytogenet 1994;73(1);8−10.17. Stamouli M.I., Panani A.D., Ferti A.D. et al. Detection of genetic alterations in primary bladder carcinoma with dual-control and multiplex fluorescence in situ hybridization. Cancer Genet Cytogenet 2004;149(2):107−13.Stamouli M.I., Panani A.D., Ferti A.D. et al. Detection of genetic alterations in primary bladder carcinoma with dual-control and multiplex fluorescence in situ hybridization. Cancer Genet Cytogenet 2004;149(2):107−13.18. Erbersdobler A., Friedrich M.G., Schwaibold H. et al. Microsatellite alterations at chromosomes 9p, 13q and 17p in nonmuscle-invasive transitional cell carcinomas of the urinary bladder. Oncol Res 1998;10(8):415−20.Erbersdobler A., Friedrich M.G., Schwaibold H. et al. Microsatellite alterations at chromosomes 9p, 13q and 17p in nonmuscle-invasive transitional cell carcinomas of the urinary bladder. Oncol Res 1998;10(8):415−20.19. Sokolova I., Halling K.C., Jenkins R.B. et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000; 2(3):116−23.Sokolova I., Halling K.C., Jenkins R.B. et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000; 2(3):116−23.20. Kipp B.R., Karnes R.J., Brankley S.M. et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 2005;173:401−4.Kipp B.R., Karnes R.J., Brankley S.M. et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 2005;173:401−4.21. Spruk C., Ohneseit P.F., Gonzalez-Zulueta M. et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54:784−8.Spruk C., Ohneseit P.F., Gonzalez-Zulueta M. et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54:784−8.22. Ishiwata S., Takahashi S., Homma Y. et al. Noninvasive detection and prediction of bladder cancer by fluorescence in situ hybridization analysis of exfoliated urothelial cells in voided urine. Urology 2001;57:811−5.Ishiwata S., Takahashi S., Homma Y. et al. Noninvasive detection and prediction of bladder cancer by fluorescence in situ hybridization analysis of exfoliated urothelial cells in voided urine. Urology 2001;57:811−5.23. Ribal M.J., Alcaraz A., Mengual L. et al. Chromosomal high-polysomies predict tumor progression in T1 transitional cell carcinoma of the bladder. Eur Urol 2004;45(5):593−9.Ribal M.J., Alcaraz A., Mengual L. et al. Chromosomal high-polysomies predict tumor progression in T1 transitional cell carcinoma of the bladder. Eur Urol 2004;45(5):593−9.24. Pycha A., Lodde M., Comploj E. et al. Intermediate-risk urothelial carcinoma: an unresolved problem? Urology 2004; 63(3):472−5.Pycha A., Lodde M., Comploj E. et al. Intermediate-risk urothelial carcinoma: an unresolved problem? Urology 2004; 63(3):472−5.25. Mian C., Lodde M., Comploj E. et al. Multiprobe-FISH: prognostic perspectives in superficial bladder cancer. JPC 2006; 59:984−7.Mian C., Lodde M., Comploj E. et al. Multiprobe-FISH: prognostic perspectives in superficial bladder cancer. JPC 2006; 59:984−7.26. Bao Q.B., Liu J., Sun H.B. et al. Clinical value of aneusomy of chromosomes in exfoliated urothelial cells to predict the recurrence of superficial bladder cancer after complete transurethral resection. Zhonghua Yi Xue Za Zhi 2009;89(8): 548−51.Bao Q.B., Liu J., Sun H.B. et al. Clinical value of aneusomy of chromosomes in exfoliated urothelial cells to predict the recurrence of superficial bladder cancer after complete transurethral resection. Zhonghua Yi Xue Za Zhi 2009;89(8): 548−51.27. Bollmann M., Heller H., Bánkfalvi A. et al. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer? BJU Int 2005; 95(9):1219−25.Bollmann M., Heller H., Bánkfalvi A. et al. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer? BJU Int 2005; 95(9):1219−25.28. Zellweger T., Benz G., Cathomas G. et al. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer 2006; 119(7):1660−5.Zellweger T., Benz G., Cathomas G. et al. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer 2006; 119(7):1660−5.29. Nguyen C.T., Litt D.B., Dolar S.E. et al. Prognostic significance of nondiagnostic molecular changes in urine detected by UroVysion fluorescence in situ hybridization during surveillance for bladder cancer. Urology 2009;73(2):347−50.Nguyen C.T., Litt D.B., Dolar S.E. et al. Prognostic significance of nondiagnostic molecular changes in urine detected by UroVysion fluorescence in situ hybridization during surveillance for bladder cancer. Urology 2009;73(2):347−50.30. Gofrit O.N., Zorn K.C., Silvestre J. et al. The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer. Urol Oncol 2008;26(3):246−9.Gofrit O.N., Zorn K.C., Silvestre J. et al. The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer. Urol Oncol 2008;26(3):246−9.31. Bergman J., Reznichek R.C., Rajfer J. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings. BJU Int 2008;101(1):26−9.Bergman J., Reznichek R.C., Rajfer J. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings. BJU Int 2008;101(1):26−9.32. May M., Hakenberg O.W., Gunia S. et al. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice. Urology 2007;70(3):449−53.May M., Hakenberg O.W., Gunia S. et al. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice. Urology 2007;70(3):449−53.33. Wolman S.R., Goldman B., Slovak M.L. et al. Aneusomy for detection of bladder cancer recurrence: a Southwest Oncology Group study. Cancer Genet Cytogenet 2007; 176(1):22−7.Wolman S.R., Goldman B., Slovak M.L. et al. Aneusomy for detection of bladder cancer recurrence: a Southwest Oncology Group study. Cancer Genet Cytogenet 2007; 176(1):22−7.34. Scacel M., Fahmy M., Brainard J.A. et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients bladder cancer and atypical or negative urine cytology. J Urol 2003;169:2101−5.Scacel M., Fahmy M., Brainard J.A. et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients bladder cancer and atypical or negative urine cytology. J Urol 2003;169:2101−5.35. Takahashi T., Lohse C.M., Pankratz S. et al. Predicting urothelial carcinoma recurrences with fluorescence in situ hybridization analysis of urine. J Urol 2002; (suppl)167:162.Takahashi T., Lohse C.M., Pankratz S. et al. Predicting urothelial carcinoma recurrences with fluorescence in situ hybridization analysis of urine. J Urol 2002; (suppl)167:162.36. Jones J.S. DNA-based molecular cytology for bladder cancer surveillance. Urology 2006; 67 (Suppl 3A).Jones J.S. DNA-based molecular cytology for bladder cancer surveillance. Urology 2006; 67 (Suppl 3A).37. Gudjonsson S., Isfoss B.L., Hansson K. et al. The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol 2008;54:402−8.Gudjonsson S., Isfoss B.L., Hansson K. et al. The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol 2008;54:402−8.38. Bas W.G. van Rhijn, Henk G. van der Poel, Theo H. van der Kwast. Cytology and urinary markers for the diagnosis of bladder cancer. Eur Urol Suppl 2009;8:536—41.Bas W.G. van Rhijn, Henk G. van der Poel, Theo H. van der Kwast. Cytology and urinary markers for the diagnosis of bladder cancer. Eur Urol Suppl 2009;8:536—41.39. Fritsche H.-M., Burger M., Dietmaier W. et al. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder. Am J Clin Pathol 2010;134:597−603.Fritsche H.-M., Burger M., Dietmaier W. et al. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder. Am J Clin Pathol 2010;134:597−603.40. Dobruch J., Theo M. de Reijke, Borówka A. Biologic markers of urothelial cell cancer of the Bladder. Central European Journal of Urology 2010/63/2.Dobruch J., Theo M. de Reijke, Borówka A. Biologic markers of urothelial cell cancer of the Bladder. Central European Journal of Urology 2010/63/2.41. Rosevear H.M., Lightfoot A.J., O’Donnell M.A. Ability of urovysion FISH analysis to select patients with lowor intermediate-risk non-muscle-invasive bladder cancer (LI-NMIBC) for decreased surveillance. J Clin Oncol 2011;29(suppl 7), abstr.Rosevear H.M., Lightfoot A.J., O’Donnell M.A. Ability of urovysion FISH analysis to select patients with lowor intermediate-risk non-muscle-invasive bladder cancer (LI-NMIBC) for decreased surveillance. J Clin Oncol 2011;29(suppl 7), abstr.42. Tilki D., Burger M., Dalbagni G. et al. Urine Markers for Detection and Surveillance of Non-Muscle-Invasive Bladder Cancer. Eur Urol 2011;60:19−28.Tilki D., Burger M., Dalbagni G. et al. Urine Markers for Detection and Surveillance of Non-Muscle-Invasive Bladder Cancer. Eur Urol 2011;60:19−28.43. Mengual L., Marín-Aguilera M., Ribal M.J. et al. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guerin therapy. Eur Urol 2007; 52:752−9.Mengual L., Marín-Aguilera M., Ribal M.J. et al. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guerin therapy. Eur Urol 2007; 52:752−9.44. Savic S., Zlobec I., Thalmann G.N. et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. Int J Cancer2009;124(12):2899−904.Savic S., Zlobec I., Thalmann G.N. et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. Int J Cancer2009;124(12):2899−904.45. Whitson J., Berry A., Carroll P. et al. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU Int 2009;104:336−9.Whitson J., Berry A., Carroll P. et al. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU Int 2009;104:336−9.